Organization
Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia
1 abstract
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Washington University School of Medicine, Department of Immunology and Oncology, Clínica Universidad de Navarra, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques),